Diabetic Retinopathy Screening


Loading - Please Wait

Diabetic Retinopathy: Patient Huddle


Loading - Please Wait

This activity is supported by an indepentdant medical education grant from Regeneron Pharmaceuticals, Inc.

Diabetic retinopathy is the leading cause of blindness in working-age adults and affects four of every ten people with diabetes. But only half of those who should be screened for diabetic retinopathy are screened, leaving the rest vulnerable to vision loss that is frequently not detected until it is too late. Timely treatment of diabetic retinopathy can reduce the risk of vision loss by 95%.

Now, primary care clinicians can screen their patients with diabetes using a special handheld camera. Images are then securely sent to an ophthalmologist who will interpret the images. Optimizing Disease Management (ODM): Diabetic Retinopathy, a Penn Medicine – Lancaster General Health quality improvement initiative, provides primary care clinicians with the tools to detect diabetic retinopathy in patients who may not otherwise be screened.

Start / Register

Activity 1: Diabetic Retinopathy Screening


  • Guidelines for and the importance of retinal screening of patients with diabetes
  • Pathophysiology of diabetic retinopathy and its consequence, diabetic macular edema
  • Treatment options and the collaborative care model

Activity 2: Diabetic Retinopathy: Patient Huddle


  • Reinforces the education delivered in the first activity
  • Clinical scenarios that reflect real-world experiences for primary care clinicians providing retinal screening for patients with diabetes
  • "Team huddle," similar to that conducted in medical home settings, providing a review of the patients' charts, goals, and treatment plans

This activity is supported by an indepentdant medical education grant from Regeneron Pharmaceuticals, Inc.

Faculty

Christian Hermansen, MD, MBA

Specialist, Diseases and Surgery of the Retina and Vitreous
Director, Diabetic Eye Care and Macular Degeneration Center at Family Eye Group
Lancaster General Health & Surgery
Lancaster, PA

Christian Hermansen, MD, Associate Director/ Regional Medical Director. Dr. "Herm" graduated from Jefferson Medical College and was introduced to Lancaster shortly thereafter. He graduated from the Lancaster General Health Family Medicine Residency Program and was honored with the Society for Teachers in Family Medicine Resident of the Year award. After two wonderful years in Christian-based private practice in New Jersey, he was called to Lancaster to combine private and academic family medicine. He also serves as Managing Physician of Downtown Family Medicine and oversees the LGHP Academic Practices as Regional Medical Director. He is a past recipient of the Faculty Teacher of the Year and serves as deacon of his church. Feel free to discuss financial peace, sports (Go Phillies, Sixers and Eagles! #TrusttheProcess #PhillyPhilly), or the book you're currently reading when you see him. After work, however, Dr. Hermansen can't wait to enjoy family life with his wife, Heather, and his three boys, Timothy, Benjamin and Nathaniel and coach baseball in the community. Follow more of the activities of the Residency Program on twitter: https://twitter.com/LGFamMedRes

Michael R. Pavlica, MD

Specialist, Diseases and Surgery of the Retina and Vitreous
Director, Diabetic Eye Care and Macular Degeneration Center at Family Eye Group
Lancaster General Health & Surgery
Lancaster, PA

Dr. Pavlica specializes in diseases and surgery of the retina and vitreous. He received his MD from New York University School of Medicine in 1990, and then completed an internal medicine internship in Boston at Beth Israel Hospital, Harvard Medical School. Dr. Pavlica completed his ophthalmology residency at Boston Medical Center, followed by two-years of fellowship training at Baylor College of Medicine in Houston, Texas.

Dr. Pavlica has extensive training in the medical and surgical management of diabetic retinopathy, macular degeneration, retinal detachments, macular holes, macular pucker, and retinal vein occlusions, among others. He is the author of the chapter Subretinal Neovascularization in the newest edition of Master Techniques in Ophthalmic Surgery. He has participated in numerous studies and published articles as an investigator with the Diabetic Retinopathy Clinical Research Network. Dr. Pavlica has authored articles in the Archives of Ophthalmology and Investigative Ophthalmology and Visual Science. A study involving various types of treatment for diabetic retinopathy in which he was an investigator has been published in the New England Journal of Medicine. He has served as a reviewer for the journal Ophthalmology and BMC Ophthalmology.

He is a member of the American Academy of Ophthalmology, the American Society of Retinal Specialists, and the American Society of Cataract and Refractive Surgeons. Dr. Pavlica is a past president of the Lancaster County Medical Society.

This activity is supported by an indepentdant medical education grant from Regeneron Pharmaceuticals, Inc.

CME/CE

Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and DKBmed, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points [and patient safety MOC credit] in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

This Enduring Material activity, Optimizing Disease Management: A Vision for Diabetic Eye Screening, has been reviewed and is acceptable for credit by the American Academy of Family Physicians. Term of approval begins 08/23/2018. Term of approval is for one year from this date. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Approved for 1.0 AAFP Prescribed credits.

Target Audience

This activity is intended for primary care clinicians and allied health providers who manage patients with type 2 diabetes.

Learning Objectives

  • Use available retina screening devices to follow the newest American Diabetes Assocation (ADA)/American Academy of Ophthalmology (AAO) guidelines on regular screening of all patients with diabetes.
  • Evaluate the pathophysiology of DR and DME to highlight the importance of early screening and treatment.
  • Differentiate between agents and classes among current and emerging therapies and work collaboratively with retina specialists to develop treatment plans based on efficacy and shared decision making.

Educational Support

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported no financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

Faculty / Presenter Reported Financial Relationship

  • Christian Hermansen, MD, MBA: none
  • Michael R. Pavlica, MD: none

Planners and Managers

The PIM planners and managers have nothing to disclose.

The following DKB planners and managers Stan Pogroszewski, and Rachel Deerr hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Jointly provided by Postgraduate Institute for Medicine and DKBmed, LLC.

Estimated time to complete each activity: 1.0 hours

Activity 1
Release Date: 8/16/18
Expiration Date: 10/1/19
Activity 2
Release Date: 8/23/18
Expiration Date: 10/1/19

Media: Internet

Method of Participating and Request for Credit

There are no fees for participation in this CME activity. To receive credit, participants must 1) read the learning objectives and disclosure statements, 2) complete the educational activity and 3) complete the post-test and activity evaluation.

Supported Browsers:
Internet Explorer 9.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above.


Presented by PIM in collaboration with DKBmed

This activity is supported by an indepentdant medical education grant from Regeneron Pharmaceuticals, Inc.

Your current email is:

To update your email address, please contact us at info@dkbmed.com.